GoAI
Get started
Ostin Technology Group Co., Ltd. logo

Ostin Technology Group Co., Ltd.

OST

NASDAQTechnologyHardware, Equipment & Parts

Open in GoAI

Latest quote

$1.695

Market data unavailable

OST company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

20

Strong Down

Sentiment

45

Mixed

Risk resilience

65

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Hardware, Equipment & Parts
Sector
Technology
Headquarters
CN

Market position

Volume
0
Market cap
10.11M USD

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends16%-1%-18%-35%Gross margin, FY2021: 10.35%Gross margin, FY2022: 11.96%Gross margin, FY2023: 3.57%Gross margin, FY2024: 5.19%Gross margin, FY2025: 6.40%Operating margin, FY2021: 1.92%Operating margin, FY2022: 0.43%Operating margin, FY2023: -17.83%Operating margin, FY2024: -29.35%Operating margin, FY2025: -22.88%Net margin, FY2021: 1.85%Net margin, FY2022: 0.19%Net margin, FY2023: -19.03%Net margin, FY2024: -30.99%Net margin, FY2025: -25.24%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 10.35%. Gross margin FY2022 11.96%. Gross margin FY2023 3.57%. Gross margin FY2024 5.19%. Gross margin FY2025 6.40%. Operating margin FY2021 1.92%. Operating margin FY2022 0.43%. Operating margin FY2023 -17.83%. Operating margin FY2024 -29.35%. Operating margin FY2025 -22.88%. Net margin FY2021 1.85%. Net margin FY2022 0.19%. Net margin FY2023 -19.03%. Net margin FY2024 -30.99%. Net margin FY2025 -25.24%.

Income trends

Revenue

39.68M USD+22.23%

Operating income

−9.08M USD+4.75%

Net income

−10.02M USD+0.46%
Income trends across reported periods185.61M USD114.14M USD42.66M USD−28.82M USDRevenue, FY2021: 167.74M USDRevenue, FY2022: 105.42M USDRevenue, FY2023: 57.53M USDRevenue, FY2024: 32.46M USDRevenue, FY2025: 39.68M USDOperating income, FY2021: 3.22M USDOperating income, FY2022: 450.42K USDOperating income, FY2023: −10.26M USDOperating income, FY2024: −9.53M USDOperating income, FY2025: −9.08M USDNet income, FY2021: 3.1M USDNet income, FY2022: 198.98K USDNet income, FY2023: −10.95M USDNet income, FY2024: −10.06M USDNet income, FY2025: −10.02M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 167.74M USD. Revenue FY2022 105.42M USD. Revenue FY2023 57.53M USD. Revenue FY2024 32.46M USD. Revenue FY2025 39.68M USD. Operating income FY2021 3.22M USD. Operating income FY2022 450.42K USD. Operating income FY2023 −10.26M USD. Operating income FY2024 −9.53M USD. Operating income FY2025 −9.08M USD. Net income FY2021 3.1M USD. Net income FY2022 198.98K USD. Net income FY2023 −10.95M USD. Net income FY2024 −10.06M USD. Net income FY2025 −10.02M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue39.68M USD32.46M USD57.53M USD105.42M USD167.74M USD
Cost of goods sold37.14M USD30.78M USD55.47M USD92.8M USD150.39M USD
Gross profit2.54M USD1.69M USD2.05M USD12.61M USD17.36M USD
Research and development2.53M USD1.7M USD2.78M USD2.52M USD5.71M USD
Selling, general, and administrative9.21M USD9.62M USD9.72M USD10.44M USD8.96M USD
Operating expenses11.62M USD11.22M USD12.31M USD12.16M USD14.14M USD
Interest expense1.59M USD1.65M USD1.27M USD1.29M USD1.11M USD
Depreciation and amortization3.39M USD4.78M USD3.2M USD2.39M USD1.93M USD
Operating income−9.08M USD−9.53M USD−10.26M USD450.42K USD3.22M USD
Net income−10.02M USD−10.06M USD−10.95M USD198.98K USD3.1M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.8

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.69-0.95-1.2-1.46Q2 '23Q1 '24Q1 '24Q3 '24Q2 '25Q1 '26Q2 '26
Q2 2023, reported Apr 9, 2023: actual -0.9, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Jan 9, 2024: actual -1.08, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual -0.75, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Sep 27, 2024: actual -0.965, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 28, 2025: actual -0.746, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Jan 26, 2026: actual -1.4, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 27, 2026: actual -0.8, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates35.84M28.37M20.9M13.43MQ2 '23Q1 '24Q1 '24Q3 '24Q2 '25Q1 '26Q2 '26
Q2 2023, reported Apr 9, 2023: actual 34.3M USD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Jan 9, 2024: actual 23.23M USD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 14.97M USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Sep 27, 2024: actual 17.49M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 28, 2025: actual 20.84M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Jan 26, 2026: actual 18.84M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 27, 2026: actual 17.5M USD, estimate —, surprise —, Comparison unavailable.

OST news

newsfilecorp.com

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling…

Read source
newsfilecorp.com

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs per year diagnosed with osteosarcoma Company expects to submit U.S. Department of Agriculture meeting request to gain…

Read source
newsfilecorp.com

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs.

Read source
newsfilecorp.com

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma during the 2026…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 5, 2025

1:25

Stock split

Effective Dec 31, 2024

1:10

OST peers

NVIDIA Corporation logo

NVDA

NVIDIA Corporation

$214.72

-0.98%

Apple Inc. logo

AAPL

Apple Inc.

$309.35

-0.63%

Microsoft Corporation logo

MSFT

Microsoft Corporation

$483.24

+0.43%

Broadcom Inc. logo

AVGO

Broadcom Inc.

$368.45

+1.21%

SK hynix Inc. logo

SKHY

SK hynix Inc.

$163.41

+0.20%

Micron Technology, Inc. logo

MU

Micron Technology, Inc.

$966.78

-0.77%

Continue in GoAI

Research OST

research.disclaimer